Skip to main content

Tokunbor Lawal, PhD, FNP-BC

Tokunbor Lawal

Tokunbor Lawal, PhD, FNP-BC

Nurse Scientist
Independent Research Scholar

Translational Biobehavioral and Health Disparities Branch
tokunbor.lawal@nih.gov
301-451-5951

Dr. Tokunbor Lawal is a Nurse Scientist and Independent Research Scholar in the Skeletal Myopathies Unit of the Translational Biobehavioral and Health Disparities Branch at the NIH Clinical Center.

BS, Biology, University of Maryland
BS, Nursing, Georgetown University
MS, Marymount University
PhD, Johns Hopkins University

Dr. Lawal completed his predoctoral work in the laboratory of Dr. Leslie Biesecker at the National Human Genome Research Institute. He completed his postdoctoral fellowship at NINR in the laboratories of Dr. Mary Engler (Vascular Biology Unit) and Dr. Katherine Meilleur (Neuromuscular Symptoms Unit) in 2019. His postdoctoral work combined basic and clinical research to develop or discover treatments for RYR1-related myopathies. He received the NIH Independent Research Scholar Award in the NINR Division of Intramural Research in 2020. A board-certified nurse practitioner, Dr. Lawal is a commissioned Corps officer with the United States Public Health Service.

Dr. Lawal’s research is focused on the development of preclinical translational models of congenital myopathies related to skeletal muscle excitation-contraction coupling defects to identify opportunities for therapeutic interventions. Dr. Lawal aims to reduce and ultimately eliminate the health inequities facing individuals with CM without approved treatments and to identify effective approaches to improve the health and quality of life of individuals with this rare and neglected group of genetic disorders.

Congenital myopathies (CM) are a heterogeneous group of early-onset neuromuscular disorders that primarily present with hypotonia, muscle weakness that includes facial muscles and often respiratory involvement. Adult-onset cases have also been described. They are frequently associated with significant lifelong morbidities that are severely disabling and can result in premature mortality. They have historically been classified based on muscle biopsy findings. Over 20 genes have been linked with CM. A key area of pathology in CM are the skeletal muscle triads that control excitation-contraction coupling. There is no approved treatment for this group of debilitating diseases. CM constitutes a group of rare (orphan) diseases (pooled prevalence: 1.5/100,000). A significant portion of genetic variations identified in individuals with CM are classified as variants of uncertain significance (VUS). While pathogenic variants have a clinically confirmed association with increased disease risk, VUS results do not. The functional consequence of harboring a VUS is not known and not clearly linked to disease. A VUS can be reclassified through functional assays that characterize the impact of such genetic variations on protein function.

Dr. Lawal’s lab aims to functionally characterize genetic VUS associated with skeletal muscle excitation-contraction coupling disorders using relevant, reliable, and cost-effective preclinical models. These preclinical models allow us to screen promising therapeutic compounds and elucidate the patho-mechanisms that can be targeted for therapeutic interventions in clinical trials.

  • NIH Independent Research Scholar Award, Division of Intramural Research, NINR; 2020

Todd JJ, Lawal TA, Chrismer IC, Kokkinis A, Grunseich C, Jain MS, Waite MR, Biancavilla V, Pocock S, Brooks K, Mendoza CJ, Norato G, Cheung K, Riekhof W, Varma P, Colina-Prisco C, Emile-Backer M, Meilleur KG, Marks AR, Webb Y, Marcantonio EE, Foley AR, Bönnemann CG, Mohassel P. Rycal S48168 (ARM210) for RYR1-related myopathies: a phase one, open-label, dose-escalation trial.(external link) EClinicalMedicine. 2024;68:102433.

Todd JJ, Lawal TA, Witherspoon JW, Chrismer IC, Razaqyar MS, Punjabi M, Elliott JS, Tounkara F, Kuo A, Shelton MO, Allen C, Cosgrove MM, Linton M, Michael D, Jain MS, Waite M, Drinkard B, Wakim PG, Dowling JJ, Bönnemann CG, Emile-Backer M, Meilleur KG. Randomized controlled trial of N-acetylcysteine therapy for RYR1-related myopathies.(external link) Neurology. 2020;94(13):e1434-e1444.

Lawal TA, Patankar A, Todd JJ, Razaqyar MS, Chrismer IC, Zhang X, Waite MR, Jain MS, Emile-Backer M, Witherspoon JW, Liu CY, Grunseich C, Meilleur KG. Ryanodine Receptor 1-Related Myopathies: Quantification of Intramuscular Fatty Infiltration from T1-Weighted MRI.(external link) J Neuromuscul Dis. 2021;8(4):657-668.

Lawal TA, Todd JJ, Witherspoon JW, Bönnemann CG, Dowling JJ, Hamilton SL, Meilleur KG, Dirksen RT. Ryanodine receptor 1-related disorders: an historical perspective and proposal for a unified nomenclature.(external link) Skelet Muscle. 2020;10(1):32.

Lawal TA, Todd JJ, Elliott JS, Linton MM, Andres M, Witherspoon JW, Collins JP, Chrismer IC, Tounkara F, Waite MR, Nichols C, Bönnemann CG, Vuillerot C, Bendixen R, Jain MS, Meilleur KG. Assessing Motor Function in Congenital Muscular Dystrophy Patients Using Accelerometry.(external link) J Neurosci Nurs. 2020;52(4):172-178.